Update on the prevention and treatment of tumor lysis syndrome
Journal of Onco-Nephrology · 2019
DOI: 10.1177/2399369319837212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Onco-Nephrology, 2019. Verfasst von Krishna Sury. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 130 Literaturangaben.
Abstract (Originalsprache)
Tumor lysis syndrome is a constellation of metabolic derangements seen when tumor cells die and release their intracellular contents into the systemic circulation. Hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia may lead to severe organ dysfunction and even death. Tumor lysis syndrome is classically considered a complication of successful cancer treatment, but it can also occur in untreated malignancies characterized by rapid proliferation. In this review, we cover the types of cancers and chemo- and immunotherapies associated with tumor lysis syndrome, the mechanisms by which severe metabolic derangements can develop, and the available treatments.
Zitieren
APA
Sury, K. (2019). Update on the prevention and treatment of tumor lysis syndrome. Journal of Onco-Nephrology. https://doi.org/10.1177/2399369319837212
Vancouver
Sury K. Update on the prevention and treatment of tumor lysis syndrome. Journal of Onco-Nephrology. 2019. doi:10.1177/2399369319837212
BibTeX
@article{Sury2019,
author = {Sury, Krishna},
title = {Update on the prevention and treatment of tumor lysis syndrome},
journal = {Journal of Onco-Nephrology},
year = {2019},
doi = {10.1177/2399369319837212}
}
EUVIMED